Fibroblast Growth Factor 23 and Heart Failure: the Plot Thickens

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2015 Nov 29

PMID 26614271

Citations 2

Authors

Orlando M Gutierrez

Affiliations

Soon will be listed here.

Citing Articles

A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies.

Netala V, Teertam S, Li H, Zhang Z Cells. 2024; 13(17.

PMID: 39273041 PMC: 11394358. DOI: 10.3390/cells13171471.

FGF23 modulates the effects of erythropoietin on gene expression in renal epithelial cells.

Yashiro M, Ohya M, Mima T, Ueda Y, Nakashima Y, Kawakami K Int J Nephrol Renovasc Dis. 2018; 11:125-136.

PMID: 29670389 PMC: 5894721. DOI: 10.2147/IJNRD.S158422.

References

Gutierrez O, Januzzi J, Isakova T, Laliberte K, Smith K, Collerone G . Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119(19):2545-52. PMC: 2740903. DOI: 10.1161/CIRCULATIONAHA.108.844506. View

Isakova T, Houston J, Santacruz L, Schiavenato E, Somarriba G, Harmon W . Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure. Pediatr Nephrol. 2013; 28(10):2035-42. PMC: 3755096. DOI: 10.1007/s00467-013-2515-7. View

Kestenbaum B, Sachs M, Hoofnagle A, Siscovick D, Ix J, Robinson-Cohen C . Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail. 2014; 7(3):409-17. PMC: 4031265. DOI: 10.1161/CIRCHEARTFAILURE.113.000952. View

Mirza M, Larsson A, Melhus H, Lind L, Larsson T . Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009; 207(2):546-51. DOI: 10.1016/j.atherosclerosis.2009.05.013. View

Touchberry C, Green T, Tchikrizov V, Mannix J, Mao T, Carney B . FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab. 2013; 304(8):E863-73. PMC: 3625783. DOI: 10.1152/ajpendo.00596.2012. View

Imazu M, Takahama H, Asanuma H, Funada A, Sugano Y, Ohara T . Pathophysiological impact of serum fibroblast growth factor 23 in patients with nonischemic cardiac disease and early chronic kidney disease. Am J Physiol Heart Circ Physiol. 2014; 307(10):H1504-11. DOI: 10.1152/ajpheart.00331.2014. View

Kao Y, Chen Y, Lin Y, Shiu R, Chao T, Chen S . FGF-23 dysregulates calcium homeostasis and electrophysiological properties in HL-1 atrial cells. Eur J Clin Invest. 2014; 44(8):795-801. DOI: 10.1111/eci.12296. View

Wohlfahrt P, Melenovsky V, Kotrc M, Benes J, Jabor A, Franekova J . Association of Fibroblast Growth Factor-23 Levels and Angiotensin-Converting Enzyme Inhibition in Chronic Systolic Heart Failure. JACC Heart Fail. 2015; 3(10):829-39. DOI: 10.1016/j.jchf.2015.05.012. View

Plischke M, Neuhold S, Adlbrecht C, Bielesz B, Shayganfar S, Bieglmayer C . Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest. 2011; 42(6):649-56. DOI: 10.1111/j.1365-2362.2011.02631.x. View

10.

van Venrooij N, Pereira R, Tintut Y, Fishbein M, Tumber N, Demer L . FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014; 29(8):1525-32. PMC: 4118139. DOI: 10.1093/ndt/gft523. View

11.

Andrukhova O, Slavic S, Odorfer K, Erben R . Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23. J Bone Miner Res. 2015; 30(10):1831-9. PMC: 4973700. DOI: 10.1002/jbmr.2527. View

12.

Di Marco G, Reuter S, Kentrup D, Grabner A, Amaral A, Fobker M . Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant. 2014; 29(11):2028-35. PMC: 4425841. DOI: 10.1093/ndt/gfu190. View

13.

Dai B, David V, Martin A, Huang J, Li H, Jiao Y . A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012; 7(9):e44161. PMC: 3435395. DOI: 10.1371/journal.pone.0044161. View

14.

di Giuseppe R, Buijsse B, Hirche F, Wirth J, Arregui M, Westphal S . Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab. 2014; 99(3):947-55. DOI: 10.1210/jc.2013-2963. View

15.

Taylor E, Rimm E, Stampfer M, Curhan G . Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011; 161(5):956-62. PMC: 3095912. DOI: 10.1016/j.ahj.2011.02.012. View

16.

Grabner A, Amaral A, Schramm K, Singh S, Sloan A, Yanucil C . Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy. Cell Metab. 2015; 22(6):1020-32. PMC: 4670583. DOI: 10.1016/j.cmet.2015.09.002. View

17.

Faul C, Amaral A, Oskouei B, Hu M, Sloan A, Isakova T . FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11):4393-408. PMC: 3204831. DOI: 10.1172/JCI46122. View

18.

Panwar B, Jenny N, Howard V, Wadley V, Muntner P, Kissela B . Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke. 2015; 46(2):322-8. PMC: 4308535. DOI: 10.1161/STROKEAHA.114.007489. View

19.

Stubbs J, He N, Idiculla A, Gillihan R, Liu S, David V . Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res. 2011; 27(1):38-46. PMC: 3439562. DOI: 10.1002/jbmr.516. View

20.

Gruson D, Ferracin B, Ahn S, Rousseau M . Comparison of fibroblast growth factor 23, soluble ST2 and Galectin-3 for prognostication of cardiovascular death in heart failure patients. Int J Cardiol. 2015; 189:185-7. DOI: 10.1016/j.ijcard.2015.04.074. View